Phase III B-MIND Study Passes Futility Analysis for Patients with DLBCL

MorphoSys announced that their ongoing phase III B-MIND study of tafasitamab passed the interim analysis for futility in patients with relapsed or refractory diffuse large B-cell lymphoma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news